Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Simcere Pharmaceutical Group stock

2096.HK
HK0000658531
A2QD9S

Price

6.60
Today +/-
+0.02
Today %
+1.79 %

Simcere Pharmaceutical Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Simcere Pharmaceutical Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Simcere Pharmaceutical Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Simcere Pharmaceutical Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Simcere Pharmaceutical Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Simcere Pharmaceutical Group Stock Price History

DateSimcere Pharmaceutical Group Price
12/17/20246.60 undefined
12/16/20246.48 undefined
12/13/20246.74 undefined
12/12/20246.63 undefined
12/11/20246.59 undefined
12/10/20246.57 undefined
12/9/20246.83 undefined
12/6/20246.62 undefined
12/5/20246.81 undefined
12/4/20246.89 undefined
12/3/20246.91 undefined
12/2/20246.52 undefined
11/29/20246.52 undefined
11/28/20246.45 undefined
11/27/20246.35 undefined
11/26/20246.22 undefined
11/25/20246.14 undefined
11/22/20246.15 undefined
11/21/20246.31 undefined
11/20/20246.38 undefined
11/19/20246.36 undefined
11/18/20246.36 undefined

Simcere Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Simcere Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Simcere Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Simcere Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Simcere Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Simcere Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Simcere Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Simcere Pharmaceutical Group’s growth potential.

Simcere Pharmaceutical Group Revenue, EBIT and net profit per share

DateSimcere Pharmaceutical Group RevenueSimcere Pharmaceutical Group EBITSimcere Pharmaceutical Group Net Income
2029e12.13 B undefined3.12 B undefined0 undefined
2028e11.38 B undefined2.83 B undefined0 undefined
2027e10.18 B undefined2.32 B undefined0 undefined
2026e8.93 B undefined1.56 B undefined1.5 B undefined
2025e7.83 B undefined1.36 B undefined1.24 B undefined
2024e6.82 B undefined1.08 B undefined961.79 M undefined
20236.61 B undefined717.71 M undefined714.76 M undefined
20226.32 B undefined815.28 M undefined930.87 M undefined
20215 B undefined233.33 M undefined1.51 B undefined
20204.51 B undefined499.21 M undefined669.53 M undefined
20195.04 B undefined1.16 B undefined1 B undefined
20184.51 B undefined851.44 M undefined733.69 M undefined
20173.87 B undefined696.65 M undefined350.41 M undefined

Simcere Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
3.874.515.044.5156.326.616.827.838.9310.1811.3812.13
-16.7311.56-10.4810.8926.514.483.1914.8014.0814.0211.796.58
84.8582.9282.3780.0478.4079.0075.4473.1063.6855.8248.9543.7941.09
3.283.744.153.613.9254.98000000
0.350.7310.671.510.930.710.961.241.5000
-109.4336.83-33.30125.26-38.29-23.2334.5928.7221.02---
-------------
-------------
2.352.352.352.392.612.622.61000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Simcere Pharmaceutical Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Simcere Pharmaceutical Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2017201820192020202120222023
             
1.081.450.93.272.182.622.02
0.70.951.341.872.42.342.64
579.85745.7467.5743.7937.3739.8950.73
187.24233.87248.17262.67235.16304.78614.56
0.240.280.341.020.130.150.31
2.783.672.96.474.985.465.64
1.181.381.872.131.932.142.17
0.820.911.221.782.652.211.58
000000100.33
65.9149.3533.7777.1159.69379.9715.79
142.47142.47142.47172.79172.79172.79142.47
205.44196.14599.79323.63366.54424.18505.96
2.412.673.874.485.185.335.21
5.26.346.7710.9410.1610.7910.85
             
000333.083.17
0000000
1.781.581.492.213.424.013.93
22.6128.0533.17-61.79-121.1455.67102.09
-20.64-39.48-47.1152.01137.45-18.912.15
1.781.571.485.36.447.137.22
215.1307.56254.85242.08323.95335.43317.22
0000000
1.31.611.51.421.181.281.27
0.140.2000.991.180.76
0.881.991.671.830.570.170.33
2.534.113.433.53.062.972.69
0.30.121.271.470.070.160.33
232.76208.42116.6193.6142.77115.29102.68
346.1332.37470.53447.95417.61403.35508.11
0.880.661.862.110.630.670.95
3.414.775.295.613.73.643.63
5.196.346.7710.9110.1410.7710.85
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Simcere Pharmaceutical Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Simcere Pharmaceutical Group's financial health and stability.

Assets

Simcere Pharmaceutical Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Simcere Pharmaceutical Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Simcere Pharmaceutical Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Simcere Pharmaceutical Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
0.50.931.080.811.40.89
104120162222251282
000000
121-210-555-717-78386
216-6384-213-1,07197
51391481417029
12315426415414-7
0.940.780.770.1-0.21.35
-292-335-507-352-209-678
-508-472-592529-43568
-216-137-85881-226746
000000
-237927467229-1,477-316
0003.1200
-0.350.31-1.012.35-1.62-0.75
-110-616-1,480-996244-46
0000-391-391
0.080.62-0.832.92-2.30.68
646.88440.6265.15-256.11-411.46676.71
000000

Simcere Pharmaceutical Group stock margins

The Simcere Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Simcere Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Simcere Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Simcere Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the Simcere Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Simcere Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Simcere Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Simcere Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Simcere Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Simcere Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Simcere Pharmaceutical Group Margin History

Simcere Pharmaceutical Group Gross marginSimcere Pharmaceutical Group Profit marginSimcere Pharmaceutical Group EBIT marginSimcere Pharmaceutical Group Profit margin
2029e75.43 %25.7 %0 %
2028e75.43 %24.87 %0 %
2027e75.43 %22.76 %0 %
2026e75.43 %17.42 %16.77 %
2025e75.43 %17.4 %15.81 %
2024e75.43 %15.9 %14.11 %
202375.43 %10.86 %10.82 %
202279.01 %12.89 %14.72 %
202178.4 %4.67 %30.14 %
202080.04 %11.07 %14.85 %
201982.36 %22.94 %19.93 %
201882.92 %18.86 %16.25 %
201784.84 %18.01 %9.06 %

Simcere Pharmaceutical Group Stock Sales Revenue, EBIT, Earnings per Share

The Simcere Pharmaceutical Group earnings per share therefore indicates how much revenue Simcere Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Simcere Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Simcere Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Simcere Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Simcere Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Simcere Pharmaceutical Group Revenue, EBIT and net profit per share

DateSimcere Pharmaceutical Group Sales per ShareSimcere Pharmaceutical Group EBIT per shareSimcere Pharmaceutical Group Earnings per Share
2029e4.8 undefined0 undefined0 undefined
2028e4.5 undefined0 undefined0 undefined
2027e4.03 undefined0 undefined0 undefined
2026e3.53 undefined0 undefined0.59 undefined
2025e3.1 undefined0 undefined0.49 undefined
2024e2.7 undefined0 undefined0.38 undefined
20232.53 undefined0.28 undefined0.27 undefined
20222.41 undefined0.31 undefined0.36 undefined
20211.91 undefined0.09 undefined0.58 undefined
20201.88 undefined0.21 undefined0.28 undefined
20192.15 undefined0.49 undefined0.43 undefined
20181.92 undefined0.36 undefined0.31 undefined
20171.65 undefined0.3 undefined0.15 undefined

Simcere Pharmaceutical Group business model

Simcere Pharmaceutical Group is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Simcere Pharmaceutical Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Simcere Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Simcere Pharmaceutical Group shares outstanding

The number of shares was Simcere Pharmaceutical Group in 2023 — This indicates how many shares 2.609 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Simcere Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Simcere Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Simcere Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Simcere Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Simcere Pharmaceutical Group dividend history and estimates

In 2023, Simcere Pharmaceutical Group paid a dividend amounting to 0.18 CNY. Dividend means that Simcere Pharmaceutical Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Simcere Pharmaceutical Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Simcere Pharmaceutical Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Simcere Pharmaceutical Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Simcere Pharmaceutical Group Dividend History

DateSimcere Pharmaceutical Group Dividend
2029e0.19 undefined
2028e0.19 undefined
2027e0.19 undefined
2026e0.19 undefined
2025e0.19 undefined
2024e0.19 undefined
20230.18 undefined
20220.18 undefined
20210.18 undefined

Simcere Pharmaceutical Group dividend payout ratio

In 2023, Simcere Pharmaceutical Group had a payout ratio of 40.35%. The payout ratio indicates the percentage of the company's profits that Simcere Pharmaceutical Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Simcere Pharmaceutical Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Simcere Pharmaceutical Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Simcere Pharmaceutical Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Simcere Pharmaceutical Group Payout Ratio History

DateSimcere Pharmaceutical Group Payout ratio
2029e41.74 %
2028e42.15 %
2027e41.7 %
2026e41.36 %
2025e43.39 %
2024e40.35 %
202340.35 %
202249.46 %
202131.24 %
202040.35 %
201940.35 %
201840.35 %
201740.35 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Simcere Pharmaceutical Group.

Simcere Pharmaceutical Group shareholders

%
Name
Stocks
Change
Date
37.61375 % Simcere Pharmaceutical Holding Ltd.950,431,68908/27/2024
24.01477 % Artking Global Ltd.606,810,03108/27/2024
4.89254 % Ren (Jin Sheng)123,625,57808/27/2024
4.78710 % Fortune Fountain Investment Ltd.120,961,37008/27/2024
0.96998 % Norges Bank Investment Management (NBIM)24,509,6381,3276/30/2024
0.78717 % The Vanguard Group, Inc.19,890,2485,513,0009/30/2024
0.64652 % Fullgoal Fund Management Co., Ltd.16,336,323-2,833,6776/30/2024
0.57776 % Bosera Asset Management Co., Ltd.14,599,000-315,0006/30/2024
0.50265 % GF Fund Management Co., Ltd.12,701,000-1,028,0006/30/2024
0.45013 % Dimensional Fund Advisors, L.P.11,374,000-271,0009/30/2024
1
2
3
4
5
...
10

Simcere Pharmaceutical Group Executives and Management Board

Mr. Renhong Tang

(42)
Simcere Pharmaceutical Group Executive Director (since 2022)
Compensation 10.55 M

Mr. Yushan Wan

(51)
Simcere Pharmaceutical Group Chief Financial Officer, Executive Director, Joint Company Secretary (since 2022)
Compensation 6.76 M

Mr. Jinsheng Ren

(53)
Simcere Pharmaceutical Group Executive Chairman of the Board, Chief Executive Officer, Founder
Compensation 1.91 M

Mr. Ruilin Song

(58)
Simcere Pharmaceutical Group Non-Executive Independent Director
Compensation 360,000

Mr. Jianguo Wang

(61)
Simcere Pharmaceutical Group Non-Executive Independent Director
Compensation 360,000
1
2
3
4

Simcere Pharmaceutical Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Vivoryon Therapeutics Stock
Vivoryon Therapeutics
SupplierCustomer0,810,110,430,040,10
Kazia Therapeutics Stock
Kazia Therapeutics
SupplierCustomer0,64-0,260,410,10-0,15
Wonderful Sky Fincl Group Stock
Wonderful Sky Fincl Group
SupplierCustomer0,24-0,45-0,48-0,290,34
Merus Stock
Merus
SupplierCustomer0,14-0,600,390,15-0,47
Inspur Stock
Inspur
SupplierCustomer0,12-0,450,29-0,01-0,61
G1 Therapeutics Stock
G1 Therapeutics
SupplierCustomer0,09-0,470,380,020,42
Hitgen A Stock
Hitgen A
SupplierCustomer-0,260,310,550,150,17
Shanghai Medicilon A Stock
Shanghai Medicilon A
SupplierCustomer-0,380,210,670,25-0,35
Fujian Foxit Software Development Joint Stock A Stock
Fujian Foxit Software Development Joint Stock A
SupplierCustomer-0,48-0,110,350,040,48
1

Most common questions regarding Simcere Pharmaceutical Group

What is the P/E ratio of Simcere Pharmaceutical Group 2024?

The Simcere Pharmaceutical Group P/E ratio is 17.9.

What is the P/S ratio of Simcere Pharmaceutical Group 2024?

The Simcere Pharmaceutical Group P/S ratio is 2.53.

What is the Quality Investing of Simcere Pharmaceutical Group?

The Quality Investing for Simcere Pharmaceutical Group is 3/10.

What is the revenue of Simcere Pharmaceutical Group 2024?

The expected Simcere Pharmaceutical Group revenue is 6.82 B CNY.

How high is the profit of Simcere Pharmaceutical Group 2024?

The expected Simcere Pharmaceutical Group profit is 961.79 M CNY.

What is the business model of Simcere Pharmaceutical Group

No history available for Simcere Pharmaceutical Group.

What is the Simcere Pharmaceutical Group dividend?

Simcere Pharmaceutical Group pays a dividend of 0.18 CNY distributed over payouts per year.

How often does Simcere Pharmaceutical Group pay dividends?

The dividend cannot currently be calculated for Simcere Pharmaceutical Group or the company does not pay out a dividend.

What is the Simcere Pharmaceutical Group ISIN?

The ISIN of Simcere Pharmaceutical Group is HK0000658531.

What is the Simcere Pharmaceutical Group WKN?

The WKN of Simcere Pharmaceutical Group is A2QD9S.

What is the Simcere Pharmaceutical Group ticker?

The ticker of Simcere Pharmaceutical Group is 2096.HK.

How much dividend does Simcere Pharmaceutical Group pay?

Over the past 12 months, Simcere Pharmaceutical Group paid a dividend of 0.18 CNY . This corresponds to a dividend yield of about 2.66 %. For the coming 12 months, Simcere Pharmaceutical Group is expected to pay a dividend of 0.19 CNY.

What is the dividend yield of Simcere Pharmaceutical Group?

The current dividend yield of Simcere Pharmaceutical Group is 2.66 %.

When does Simcere Pharmaceutical Group pay dividends?

Simcere Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Simcere Pharmaceutical Group?

Simcere Pharmaceutical Group paid dividends every year for the past 0 years.

What is the dividend of Simcere Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.19 CNY are expected. This corresponds to a dividend yield of 2.91 %.

In which sector is Simcere Pharmaceutical Group located?

Simcere Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Simcere Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Simcere Pharmaceutical Group from 7/15/2024 amounting to 0.02 CNY, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Simcere Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 7/15/2024.

What was the dividend of Simcere Pharmaceutical Group in the year 2023?

In the year 2023, Simcere Pharmaceutical Group distributed 0.176 CNY as dividends.

In which currency does Simcere Pharmaceutical Group pay out the dividend?

The dividends of Simcere Pharmaceutical Group are distributed in CNY.

All fundamentals about Simcere Pharmaceutical Group

Our stock analysis for Simcere Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Simcere Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.